Brainstorm Cell Therapeutics Inc. (BCLI) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side – The Broch Herald

Since Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and PolarityTE Inc. (NASDAQ:PTE) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of both companies.

Earnings & Valuation

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and PolarityTE Inc. (NASDAQ:PTE)s net margins, return on equity and return on assets.

Volatility and Risk

Brainstorm Cell Therapeutics Inc.s 1.19 beta indicates that its volatility is 19.00% more volatile than that of Standard and Poors 500. From a competition point of view, PolarityTE Inc. has a 1.14 beta which is 14.00% more volatile compared to Standard and Poors 500.

Liquidity

Brainstorm Cell Therapeutics Inc. has a Current Ratio of 1 and a Quick Ratio of 1. Competitively, PolarityTE Inc.s Current Ratio is 5.6 and has 5.6 Quick Ratio. PolarityTE Inc.s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

Brainstorm Cell Therapeutics Inc. and PolarityTE Inc. Recommendations and Ratings are available on the next table.

Brainstorm Cell Therapeutics Inc.s consensus target price is $9, while its potential upside is 129.01%. On the other hand, PolarityTE Inc.s potential upside is 235.69% and its consensus target price is $9.5. The results provided earlier shows that PolarityTE Inc. appears more favorable than Brainstorm Cell Therapeutics Inc., based on analyst belief.

Insider & Institutional Ownership

Roughly 11.4% of Brainstorm Cell Therapeutics Inc. shares are owned by institutional investors while 45.6% of PolarityTE Inc. are owned by institutional investors. Insiders owned roughly 0.6% of Brainstorm Cell Therapeutics Inc.s shares. Competitively, 33% are PolarityTE Inc.s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance while PolarityTE Inc. has -64.71% weaker performance.

Summary

On 7 of the 11 factors Brainstorm Cell Therapeutics Inc. beats PolarityTE Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:
Brainstorm Cell Therapeutics Inc. (BCLI) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side - The Broch Herald